Author Archives: Patricia Silva PhD

Actelion European MAA for PAH Drug Selexipag Pending Approval

Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working…

Study Finds Idiopathic Pulmonary Fibrosis Has the Worst Outcome in Patients with Diffuse Parenchymal Lung Diseases

A recent study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience,” published in the journal Lung India, compared the clinical spectrum of diffuse parenchymal lung diseases (DPLD) with idiopathic pulmonary fibrosis…

UC San Diego Health System Launches First US CTEPH Registry

The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary…

Ikaria Signs New Partnership to Expand Inomax for Severe PH in Asia

Critical care company Ikaria, Inc. and biopharmaceutical company Lee’s Pharmaceutical Holdings Limited (Lee’s Pharm) have just signed signed a new agreement to drive the registration and commercial approval of INOMAX® (nitric oxide), a breakthrough inhaled treatment of hypoxic respiratory failure (HRF), in China, Hong Kong, Macau and Taiwan. The drug will be offered as a Total Care…

Novel Surgical CTEPH Treatment Approach Cures Disease

Vanderbilt Heart & Vascular Institute (VHVI) is offering a novel and specialized surgical approach for treating patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that can cause breathing difficulties, acute pulmonary embolism, or blood clots in the lung. Even though the condition…

Sildenafil Improves Pulmonary Hypertension Outcome in Premature Babies

November is Prematurity Awareness Month, and in light of World Prematurity Day celebrated yesterday, November 17, Nationwide Children’s Hospital shared with the pulmonary hypertension community the benefits of administering Sildenafil to premature newborn babies with pulmonary hypertension. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor more popularly…

Early Pulmonary Hypertension Diagnosis Saves Running Enthusiast

Photo of Roseanne Huber from http://phadailybeat.blogspot.pt The Pulmonary Hypertension Association recently reached out to running enthusiast and pulmonary hypertension patient Roseanne Huber from Florida to share her insightful story of taking control of her condition. Huber was diagnosed with the life-threatening disease in 2006…